<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370291</url>
  </required_header>
  <id_info>
    <org_study_id>20110526-08</org_study_id>
    <nct_id>NCT01370291</nct_id>
  </id_info>
  <brief_title>Repetitive Transcranial Magnetic Stimulation for First-episode Schizophrenia Patients</brief_title>
  <acronym>rTMSfMRI</acronym>
  <official_title>Repetitive Transcranial Magnetic Stimulation (rTMS) for First-episode Schizophrenia Patients:A Double-blinded , Randomized and Functional Magnetic Resonance Imaging (fMRI)Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effects of repetitive transcranial magnetic
      stimulation(rTMS)in the first-episode Schizophrenic patients: the clinical and MRI findings
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS</measure>
    <time_frame>1-6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total AHRS score</measure>
    <time_frame>1-6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAMD Score</measure>
    <time_frame>1-6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI</measure>
    <time_frame>1-6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fMRI</measure>
    <time_frame>0,6 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>active Risperidone and active rTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active Risperidone and active rTMS for the first-episode schizophrenia patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active rTMS and sham Risperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active rTMS and sham Risperidone for the first-episode schizophrenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham rTMS and active Risperidone</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham rTMS and active Risperidone for the first-episode schizophrenia patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>active Risperidone and active rTMS</intervention_name>
    <description>active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)</description>
    <arm_group_label>active Risperidone and active rTMS</arm_group_label>
    <other_name>Risperidone:Xian-Janssen pharmaceutical ltd</other_name>
    <other_name>rTMS:MagVenture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>active rTMS and sham Risperidone</intervention_name>
    <description>active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)</description>
    <arm_group_label>active rTMS and sham Risperidone</arm_group_label>
    <other_name>Risperidone:Xian-Janssen pharmaceutical ltd</other_name>
    <other_name>rTMS: MagVenture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham rTMS and active Risperidone</intervention_name>
    <description>active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)</description>
    <arm_group_label>sham rTMS and active Risperidone</arm_group_label>
    <other_name>Risperidone:Xian-Janssen pharmaceutical ltd</other_name>
    <other_name>rTMS: MagVenture</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 16-45 years

          -  Diagnosis of schizophrenia according to DSM-IV criteria(by a board-certified
             psychiatrist)

          -  PANSS&gt;=60

          -  First episode, and the patients haven't use any antipsychotic drugs

        Exclusion Criteria:

          -  Suicide risk

          -  Diagnose of substance abuse/dependance

          -  Severe uncontrolled organic disease that may interfere in the patient´s participation
             in the study

          -  Contraindication to TMS:

               1. Implanted pacemaker

               2. Medication pump

               3. Vagal stimulator

               4. Deep brain stimulator

               5. Metallic hardware in the head or scalp: shrapnel, surgical clips, or fragments
                  from welding

               6. Signs of increased intracranial pressure

          -  Pregnancy or lactating; note that a negative pregnancy test will be required if the
             patient is a female in reproductive years

          -  Estimated IQ less than 80

          -  Have a sibling or parent with epilepsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingrong Tan, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Department of Psychiatry, Xi Jing hospital, Xi'an, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunchun Chen, Ph.D</last_name>
    <phone>+086-13720582601</phone>
    <email>Yunchunchen@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shufang Feng, Ph.D</last_name>
    <phone>+086-13227807801</phone>
    <email>fangshuan1984@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yun chun Chen</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yun chun Chen, Ph.D</last_name>
      <phone>+086-13720582601</phone>
      <email>Yunchunchen@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Shufang Feng, Ph.D</last_name>
      <phone>+086-13227807801</phone>
      <email>fangshuan1984@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Min Xi, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yun chun Chen</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun chun Chen, Ph.D</last_name>
      <phone>+086-13720582601</phone>
      <email>Yunchunchen@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Shufang Feng, Ph.D</last_name>
      <phone>+086-13227807801</phone>
      <email>fangshuan1984@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Min Xi, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <last_update_submitted>February 13, 2012</last_update_submitted>
  <last_update_submitted_qc>February 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>fengshufang</investigator_full_name>
    <investigator_title>Fourth Military Medical University, Department of Psychiatry, Xi Jing hospital</investigator_title>
  </responsible_party>
  <keyword>rTMS</keyword>
  <keyword>Risperidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

